Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2020-07-01
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Telehealth can help to mitigate this risk by minimizing the amount of face-to-face interactions. The WHO mentioned telemedicine among essential services in "strengthening the Health Systems Response to COVID-19" policy. The aim in this study is to study the effectiveness of telemedicine in managing mild COVID cases regarding isolation measures, symptoms, medications adherence, and reporting of red flags and side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of COVID-19 Pandemic on Vaccination Compliance
NCT04618796
Using Telemedicine to Optimize Teamwork and Infection Control of Critical and Highly-infectious Patients in an Emergency Department
NCT04591873
The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department
NCT01247519
Parental Compliance After Telephone Triage Advice During and After Confinement During the COVID-19 Epidemic in France
NCT04656444
Improving Nighttime Access to Care and Treatment; Part 4-Haiti
NCT05480930
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To assess the effectiveness of follow up of mild COVID-19 cases in home isolation
* To assess the applicability of telemedicine tools in the follow up of those patients and early identification of warning symptoms needing more intensive management measures.
* To assess the clinical characteristics for mild COVID-19 cases and post covid sequelae and the course of symptoms
* To assess the persistence of symptoms during follow up.
* To assess the quality of life during home management period.
* To assess cost-effectivenes of home isolation vs hospital admission in mild COVID-19 cases.
Study population \& Sample size :
The study includes 400 Adult (18-65 years) Egyptian patients with mild COVID 19 diagnosed by PCR consented (oral consent) to home isolation to follow them.
Study Design:
Prospective observational study.
Methods:
• All patients will be subjected to thorough history and clinical examination. 400 adult mild COVID cases consented to home isolation to follow them by: phone calls, what's app, hot line for emergency, Triage sheet, zoom meetings.
Patients will be given brochures about home isolation (by Egyptian MOH), list of medications, plan of follow up.
1. Daily follow up for: fever chart, report any new symptoms or progression of previously present symptom or presence of red flags.
2. Blood samples will be obtained and CT chest will be done according to the usual protocol.
3. Patients will be followed for 3 months to detect post covid sequelae and the course of symptoms (and the persistence of any symptoms).
4. Questionnaire will be done to assess the patients' commitment to the advices and regulations of home isolation as well as forms to assess fatigue and the quality of life (36-Item Short Form Survey; SF-36).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No fever (oral, below or equal 37.50 C )
3. No shortness of breath (Respiratory rate 12-20/min)
4. Oxygen saturation \>= 96 %
5. CT chest: Normal
6. Labs: D-dimer\<1000ng/ml, CPK\< twice upper limit of normal, CRP\<100, LDH\<245, Ferritin\<500, absolute lymphocytic count \>0.8
Exclusion Criteria
2. Children and young \< 18 years.
3. Age \>65 years.
4. Presence of any of the previously mentioned comorbidities.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Tharwat Hegazy
Lecturer of Internal Medicine, Rheumatology and Clinical Immunology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ibrahim El Ebrashy, Professor
Role: PRINCIPAL_INVESTIGATOR
Internal Medicine Department, Faculty of Medicine, Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine Cairo University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Dahly DL, Damen JAA, Debray TPA, de Jong VMT, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Heus P, Kammer M, Kreuzberger N, Lohmann A, Luijken K, Ma J, Martin GP, McLernon DJ, Andaur Navarro CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, Tzoulaki I, van Kuijk SMJ, van Bussel B, van der Horst ICC, van Royen FS, Verbakel JY, Wallisch C, Wilkinson J, Wolff R, Hooft L, Moons KGM, van Smeden M. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020 Apr 7;369:m1328. doi: 10.1136/bmj.m1328.
Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020 Mar 18;24(1):108. doi: 10.1186/s13054-020-2833-7. No abstract available.
Lee C, Chen D, Katz RL. Characteristics of nondepolarizing neuromuscular block: (I) post-junctional block by alpha-bungarotoxin. Can Anaesth Soc J. 1977 Mar;24(2):212-9. doi: 10.1007/BF03006234.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Telemedicine in Mild COVID-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.